AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04626063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
Study NCT01335308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Dose Motivational Interviewing
Description: Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
Study NCT00825370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
Study NCT00825370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV opioid
Description: Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
Study NCT02487875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Study NCT02487875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Study NCT02226965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNT2258
Study NCT05150132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)
Description: All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group
Study NCT05150132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)
Description: All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.
Study NCT05150132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)
Description: All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
Study NCT00794586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTI, AZLI
Description: Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
Study NCT00794586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, AZLI
Description: Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
Study NCT03354845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Deprescribing intervention
Description: Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
Study NCT00666562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Defined Green Tea Catechin Extract
Description: Given orally
Study NCT00666562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00666562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01335308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher Dose Motivational Interviewing
Description: Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
Study NCT00666562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00666562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00355797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rate Adaptive (R) Technology
Description: Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.
Study NCT00355797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rate adaptive (DDD) pacing
Description: Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
Study NCT04279353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: this intervention is a 4 weeks program with logbook and follow up during intervention
Study NCT01526330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618
Description: A mg/disc
Study NCT01526330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618
Description: B mg/disc
Study NCT01526330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618
Description: C mg/disc
Study NCT01526330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg/disc
Study NCT02294604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ethyl alcochol, chlorhexidine and moisturizers
Study NCT02294604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Study NCT02294604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: povidone-iodine
Study NCT05213156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxatrex
Description: 0.3% ofloxacin eye drops in single doses
Study NCT05213156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxatrex
Description: 0.3% ofloxacin eye drops in single doses
Study NCT02368639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare PAP Device
Description: The device is a modified version of the Fisher \& Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
Study NCT05334173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb
Description: The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.
Study NCT01841554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioband
Study NCT02110394 — intervention group
Intervention type: OTHER
Intervention: bendamustine
Description: Routine practice
Study NCT02110394 — intervention group
Intervention type: OTHER
Intervention: rituximab
Description: Routine practice
Study NCT03644888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycle ergometer training
Description: Already in arm/group descriptions
Study NCT03644888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training
Description: Already in arm/group descriptions
Study NCT03644888 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cycle ergometer training
Description: Already in arm/group descriptions
Study NCT00666562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT03947411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate
Description: Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
Study NCT03947411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping injection+Oseltamivir Phosphate
Description: Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
Study NCT00666562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given orally
Study NCT00666562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02326883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training
Description: The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
Study NCT02326883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
Study NCT03442062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment Feedback Incentives and eXchange
Description: The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
Study NCT03455790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aerobic Capacity
Description: Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests.
Study NCT03442062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician-to-physician engagement
Description: Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
Study NCT03442062 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Intervention Control
Description: Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
Study NCT01820832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol 0.5 ug/BIW for 24 weeks.
Study NCT02467244 — intervention group
Intervention type: DRUG
Intervention: Levothyroxine
Description: At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
Study NCT02107898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Study NCT02107898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Study NCT02107898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT04969055 — intervention group
Intervention type: OTHER
Intervention: Not
Description: Not
Study NCT03455790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Aerobic Capacity
Description: Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests.
Study NCT02107898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT02552602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin A
Description: Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
Study NCT02552602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin B
Description: Multivitamin containing 22 micronutrients at RDA
Study NCT02552602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin C
Description: Multivitamin containing 22 micronutrients at three times the RDA
Study NCT03515187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate ophthalmic solution
Description: one to two drops in eye, four times per day
Study NCT03515187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% sodium bromide solution
Description: one to two drops in eye, twice per day
Study NCT03515187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meibomian gland massage
Description: Physiotherapy
Study NCT03515187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT01140087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Face Transplant
Description: Transplantation of donor facial skin, tissue, muscle, and bone as needed
Study NCT03987945 — intervention group
Intervention type: DEVICE
Intervention: left atrial appendage occlusion devices
Description: All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
Study NCT01665937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen.
Study NCT02412865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit4Baby
Study NCT02412865 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text4Baby
Study NCT03012776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Posterior Spine System (TOPS)
Description: Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
Study NCT03012776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Lumbar Interbody Fusion (TLIF)
Description: Fusion with placement of interbody cage and posterolateral instrumentation
Study NCT01873144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine 1/1000
Description: Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
Study NCT01873144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 1/1000
Description: Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
Study NCT01873144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSS 3%
Description: Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
Study NCT01873144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC
Description: Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
Study NCT01873144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS (0.9%)
Description: Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
Study NCT02412865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text4Baby
Study NCT02876978 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T Cells
Description: Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
Study NCT02876978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day x 4 days
Study NCT02876978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2/day x 2 days
Study NCT02136589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dicrofenac and travoprost
Description: dicrofenac drop 3 times a day travoprost 0.005% once daily
Study NCT01240694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-33457
Description: CEP-33457 will be administered subcutaneously per dose specified in the arm description.
Study NCT02590783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental intervention surgery
Description: Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).